News | April 23, 2008

Mayo Clinic, VCU Successful in 100 Percent of CardioWest Implants in 2007

April 24, 2008 - SynCardia Systems Inc., the manufacturer of the CardioWest temporary Total Artificial Heart (TAH-t), has recognized Mayo Clinic Arizona and Virginia Commonwealth University Medical Center as 'CardioWest 100 Percent Centers for 2007' for a 100 percent success rate in CardioWest artificial heart implants in 2007.

The CardioWest artificial heart is approved as a bridge-to-transplant for patients dying from end stage biventricular failure. These patients are often days, if not hours from death. Their survival depends on receiving a donor heart, or a CardioWest artificial heart as a bridge to human heart transplant.

Vigneshwar Kasirajan, M.D., chair of Cardiothoracic Surgery for VCU Medical Center, has reached this milestone two years in row. Since VCU Medical Center became CardioWest certified on April 3, 2006, they have bridged eight of their CardioWest patients to transplant four in 2006 and four in 2007.

"SynCardia's CardioWest TAH-t is capable of supporting the sickest of patients with outstanding survival," said Dr. Kasirajan. "We are honored to be a part of this award and a part of this CardioWest program."

Mayo Clinic Arizona became a CardioWest certified center on Aug. 22, 2007. Since then, Heart Transplant Program Surgical Director Francisco Arabia, M.D., and his team have bridged all five of their CardioWest patients to transplant.

"Our success with this device is a tribute to both our expert medical staff and the proven life-saving capabilities of this device,"? said Dr. Arabia. "With the TAH-t, we can help some of the sickest patients get a second chance at life."

For more information: www.syncardia.com

Related Content

Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
St. Jude Medical, HeartMate 3 LVAS, MOMENTUM 3 IDE study results, AHA Scientific Sessions 2016
News | Ventricular Assist Devices (VAD)| December 08, 2016
St. Jude Medical Inc. announced results of the MOMENTUM 3 U.S. IDE Clinical Study during a late-breaking clinical trial...
SynCardia, Chapter 11 reorganization, sale, Total Artificial Heart
News | Artificial Heart| September 13, 2016
August 29, 2016 — SynCardia Systems, manufacturer of the...
Carmat, bioprosthetic artificial heart, PIVOTAL study, first implantation, heart failure
News | Artificial Heart| September 09, 2016
Carmat announced that the first implantation of its bioprosthetic artificial heart within the framework of the PIVOTAL...
SynCardia acquired, Versa Capital Management, chapter 11
News | Business| July 07, 2016
SynCardia Systems Inc. announced that it has entered into an asset purchase agreement (“APA”) with an affiliate of...
SynCardia Total Artificial Heart, TAH-t, documentary, Retro Reports, The New York Times
News | Artificial Heart| March 24, 2016
March 24, 2016 — A new documentary produced by Retro Report for The New York Times looks at the history and
Bryan Tyo, Baylor University Medical Center, bridge to transplant, Total Artificial Heart
News | Artificial Heart| March 18, 2016
A surgical team at Baylor University Medical Center at Dallas successfully performed a heart transplant on a patient...
HeartWare, ENDURANCE2 trial, destination therapy, HVAS, HeartWare Ventricular Assist System
News | Ventricular Assist Devices (VAD)| August 11, 2015
HeartWare International Inc. announced that enrollment in the ENDURANCE2 destination therapy clinical trial has been...
News | January 30, 2015
SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the...
Overlay Init